Wednesday, October 5, 2011
Dynavax gets $3M in reworked asthma deal with AstraZeneca
Dynavax Technologies Corp. will receive $3 million upfront after the Berkeley drug developer and pharmaceutical giant AstraZeneca amended a deal to accelerate a trial on an experimental asthma treatment.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment